Market capitalization | $1.01b |
Enterprise Value | $760.73m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.67 |
P/S ratio (TTM) P/S ratio | 4.85 |
P/B ratio (TTM) P/B ratio | 2.76 |
Revenue growth (TTM) Revenue growth | 29.35% |
Revenue (TTM) Revenue | $207.11m |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 207 207 |
29%
29%
|
|
Gross Profit | 178 178 |
17%
17%
|
|
EBITDA | -26 -26 |
71%
71%
|
EBIT (Operating Income) EBIT | -46 -46 |
49%
49%
|
Net Profit | -50 -50 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Head office | Canada |
CEO | Peter Greenleaf |
Employees | 300 |
Founded | 1993 |
Website | www.auriniapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.